Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, et al. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia 2021;41:979-990.
PMID: 33874756